AHA 2024 - Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. “BROOKLYN shows us that we get many more patients with FH to treatment targets by adding the CETP inhibitor obicetrapib to their therapy”, says Stephen Nicholls.
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
Overview
AHA 2024 - Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. “BROOKLYN shows us that we get many more patients with FH to treatment targets by adding the CETP inhibitor obicetrapib to their therapy”, says Stephen Nicholls.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms
Evaluating Sleep Deprivation as a Risk Factor for Postpartum Depression
Reducing the Risk of Postpartum Depression Through Sleep Interventions
mIDH Gliomas Explained: Characteristics and Management Strategies
From Diagnosis to Treatment: Challenges in Glioblastoma Care
Improving the IUD Experience: Evidence-Based Pain Management Approaches
Diagnosing and Treating Benign Prostatic Hyperplasia and Overactive Bladder
Bladders, Breakthroughs, and Bold New Therapies: Key Updates at AUA 2025
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?